CLAIMS

1. An anti-CTLA-4 antibody comprising a heavy chain comprising the sequence set forth in SEQ ID NO: 3, 5, 6 or 8, and a light chain comprising the sequence set forth in SEQ ID NO: 2.

2. The anti-CTLA-4 antibody of claim 1, comprising a heavy chain comprising the sequence set forth in SEQ ID NO: 6, and a light chain comprising the sequence set forth in SEQ ID NO: 2.

3. An anti-CTLA-4 antibody comprising a heavy chain comprising the sequence set forth in one of SEQ ID NOS: 14-18, and a light chain comprising the sequence set forth in one of SEQ ID NOS: 10-12.

4. Use of the anti-CTLA-4 antibody of any one of the preceding claims in the manufacture of a medicament for cancer immunotherapy, wherein the anti-CTLA-4 antibody is to be used either alone or in combination with one or more other therapies.

5. The use of claim 4, wherein the other therapy is an antibody that binds to PD-1 or PD-L1.

6. The use of claim 5, wherein the anti-PD-1 antibody is Nivolumab or Pembrolizmab.

7. Use of an anti-CTLA-4 antibody of any one of claims 1-5 in the manufacture of a medicament for treating cancer.